Compare Abeona Therapeutics Inc (ABEO) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lufax Holding Ltd — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Lufax Holding Ltd trades at $1.52 (market cap $2.41B). The key difference: Lufax Holding Ltd is far larger — about 5.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | LU | |
|---|---|---|
Market Cap | $421.19M | $2.41B |
Sector | Health | Technology |
52-Week High | $7.45 | $4.40 |
52-Week Low | $4.17 | $1.23 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Lufax Holding Ltd (LU) trades at $1.53, down 7.83% over the past day, reflecting ongoing investor caution amid financial losses and legal challenges. The stock shows a bullish technical signal with moving averages supporting an uptrend, but fundamentals remain weak with a net loss of $2.1 billion in 2025 and negative profit margins. Recent news highlights board changes and a securities class action lawsuit, adding to uncertainty.
The outlook for LU is clouded by persistent unprofitability and legal risks, though low valuation ratios like P/S of 0.39 and P/B of 0.11 may attract value investors. Analysts are predominantly bullish with 69% buy ratings, but the stock faces significant headwinds from operational losses and regulatory scrutiny, requiring careful risk assessment for any investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
